1.A Case with Diabetic Hyperosmolar Nonketotic Coma Who Developed Acute Renal Failure Secondary to Rhabdomyolysis.
Jeong Ken PARK ; Gyung Suk KIM ; Sang Yeol SUH ; Heung Suk KO ; Jin Su JO
Korean Journal of Medicine 1997;52(5):716-721
Rhabdomyolysis is defined as skeletal muscle injury with release of muscle cell constituents into the plasma and may lead to acute renal failure secondary to myoglobinuria. The most sensitive marker of muscle cell damage is serum creatine kinase concentration. It was first described by Bywaters and Beall in association with crush injuries during the second world war, and since then it has been recognized as the cause of about 5 % of all cases of acute renal failure. But acute renal failure is extremely rare in diabetic patient with hyperosmolarity irrespective of the frequency of rhabdomyolysis. Since osmotic diuresis, which is provoked by a high renal glucose load, prevents the development of acute tubular necrosis; there have been a few case reports connecting diabetic hyperosmolar state with acute renal failure, secondary to rhabdomyolysis. We reported a case with diabetic hyperosmolar nonketotic coma who developed acute renal failure secondary to rhabdomyolysis and myoglobinuria in a 60 year old patient with review of the literatures.
Acute Kidney Injury*
;
Coma*
;
Creatine Kinase
;
Diuresis
;
Glucose
;
Humans
;
Middle Aged
;
Muscle Cells
;
Muscle, Skeletal
;
Myoglobinuria
;
Necrosis
;
Plasma
;
Rhabdomyolysis*
;
World War II
2.Protracted Venous Infusion of 5-Fluorouracil as a Chemotherapy in Colorectal Cancer.
Hyun Sik JEONG ; Won Seog KIM ; Sook In JUNG ; Jong Tae LEE ; Ki Hyun KIM ; Sung Soo YOON ; Won Ki KANG ; Hong Ghi LEE ; Ken Chil PARK ; Poong Lyul RHEE ; Hae Jun KIM ; Ho Kyun CHUN ; Chan Hyung PARK
Journal of the Korean Cancer Association 1999;31(1):120-125
PURPOSE: The administration of 5-fluorouracil (5-FU) by protracted intravenous infusion is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancers. This study was performed to evaluate the response rate and toxicities of protracted infusion of 5-FU in patients with advanced or recurrent colorectal cancers who had been treated with 5-FU by bolus or shortterm continuous administration. MATERIALS AND METHODS: Between March 1995 and June 1997, twenty-eight patients with advanced colorectal cancer previously exposed to 5-FU based chemotherapy were enrolled in this triaL Patients received 5-FU (250 mg/m(2)/day days 1-28) or 5-FU plus leucovorin (5-FU; 200 mg/m/day days 1-28, leucovorin; 20 mg/m IV days 1, 8, 15, 21) by ambulatory infusion pump. Treatment course was repeated every 42 days until disease progression. RESULT: Twenty-eight patients entered. All 28 patients were assessable for response and toxicity. Five (19%) patients achieved a partial response, with the median response duration of 15 weeks (range; 7-22 weeks), and median survival time of entire patients was 54 weeks (range 7-151+ weeks). Gastrointestinal toxicity, specifically stomatitis was a major toxicity (grade 2, 12%; grade 3, 4%), but hand-foot syndrome was less frequent (5%) compared with other trials with protracted infusion of 5-FU reported in the literature. Hematologic toxicity was generally of low grade. CONCLUSION: Prolonged intravenous infusion of 5-FU can produce a response rate of 19% with low toxicity among patients refractory to bolus or short-term infusion of S-FU.
Colorectal Neoplasms*
;
Disease Progression
;
Drug Therapy*
;
Fluorouracil*
;
Hand-Foot Syndrome
;
Humans
;
Infusion Pumps
;
Infusions, Intravenous
;
Leucovorin
;
Stomatitis
3.Reference Equations for the Six-Minute Walk Distance in Healthy Korean Adults, Aged 22-59 Years.
Ah Lim KIM ; Jae Choon KWON ; In PARK ; Ji Na KIM ; Jong Min KIM ; Bi Na JEONG ; Sung Ken YU ; Byung Ki LEE ; Yeon Jae KIM
Tuberculosis and Respiratory Diseases 2014;76(6):269-275
BACKGROUND: The six-minute walk test has been widely used in people with chronic cardiopulmonary disorders as an outcome assessment with regards to therapeutic or prognostic determinants. This study was undertaken to determine the six-minute walk distance (6MWD) in a sample of healthy Koreans and to create a reference equation. We also compared the 6MWD of our cohort with previously published equations. METHODS: Two hundred fifty-nine healthy subjects (95 males) aged 22-59 years performed two walking tests using a standardized protocol. 6MWD was defined as the greatest distance achieved from the two tests. The effect of anthropometrics on the 6MWD was also investigated. RESULTS: The average 6MWD was 598.5+/-57.92 m, with significantly longer distances by males (628.9+/-59.51 m) than females (580.9+/-47.80 m) (p<0.001). Age, height, weight, and body mass index were significantly correlated with 6MWD in univariate analysis. Stepwise multiple regression showed height to be single independent predictor of 6MWD (r2=0.205, p<0.001). The reference equations derived in Caucasian and North African populations tend to overestimate the distance walked by Korean subjects, while Asian equations underestimate it. CONCLUSION: The average 6MWD in these Korean populations was 600 m. The regression equation revealed that individual's height was the most significant predictor of distance, explaining 20.5% of the distance variance.
Adult*
;
Asian Continental Ancestry Group
;
Body Mass Index
;
Cohort Studies
;
Exercise Test
;
Exercise Tolerance
;
Female
;
Healthy Volunteers
;
Humans
;
Male
;
Physical Endurance
;
Reference Values
;
Walking
4.The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid
Jae Young LEE ; Yasunori MINAMI ; Byung Ihn CHOI ; Won Jae LEE ; Yi-Hong CHOU ; Woo Kyoung JEONG ; Mi-Suk PARK ; Nobuki KUDO ; Min Woo LEE ; Ken KAMATA ; Hiroko IIJIMA ; So Yeon KIM ; Kazushi NUMATA ; Katsutoshi SUGIMOTO ; Hitoshi MARUYAMA ; Yasukiyo SUMINO ; Chikara OGAWA ; Masayuki KITANO ; Ijin JOO ; Junichi ARITA ; Ja-Der LIANG ; Hsi-Ming LIN ; Christian NOLSOE ; Odd Helge GILJA ; Masatoshi KUDO
Ultrasonography 2020;39(3):191-220
The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management.